Kyntra Bio
KYNB
192 hedge funds and large institutions have $4.05B invested in Kyntra Bio in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 78 increasing their positions, 56 reducing their positions, and 22 closing their positions.
64% more capital invested
Capital invested by funds: $2.47B → $4.05B (+$1.58B)
39% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 56
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0.51% more ownership
Funds ownership: 2.59% → 3.1% (+0.51%)
1% less funds holding
Funds holding: 193 → 192 (-1)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
6% less call options, than puts
Call options by funds: $32.4M | Put options by funds: $34.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$523M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.4M |
| 3 |
PC
PointState Capital
New York
|
+$20.2M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$19.1M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$31.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$12.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.8M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$10.4M |
| 5 |
Two Sigma Investments
New York
|
-$9.39M |
KYNB Hedge Fund Activity: Q2 2018 in Review
192 of the 4,384 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2018, worth a combined $4.05B — up 64% from $2.47B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of KYNB and 21 opened new positions — a net loss of 1 holder — while 56 trimmed existing stakes and 78 added.
The largest buyer was Fidelity Investments, adding an estimated $523M. The largest seller was Janus Henderson Group, cutting an estimated $31.5M.
- 192 institutional investors held Kyntra Bio (KYNB) as of Q2 2018, down from 193 in Q1 2018.
- Funds reported $4.05B of Kyntra Bio stock for Q2 2018, up 64% quarter-over-quarter.
- 21 funds opened new Kyntra Bio positions in Q2 2018 and 22 closed out, a net change of -1 holder.
- The largest Kyntra Bio buyer in Q2 2018 was Fidelity Investments, an estimated $523M added.
- The largest Kyntra Bio seller in Q2 2018 was Janus Henderson Group, an estimated $31.5M sold.
Based on aggregated 13F filings for Q2 2018.